Licochalcones extracted from *Glycyrrhiza inflata* inhibit platelet aggregation accompanied by inhibition of COX-1 activity

Asa Okuda-Tanino¹, Daiki Sugawara², Takumi Tashiro², Masaya Iwashita¹, Yutaro Obara¹,²*, Takahiro Moriya¹, Chisato Tsushima¹, Daisuke Saigusa², Yoshihisa Tomioka², Kuniaki Ishii³, Norimichi Nakahata¹

¹ Department of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan, ² Department of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan, ³ Department of Pharmacology, Yamagata University School of Medicine, Yamagata, Japan

* obaray@med.id.yamagata-u.ac.jp

Abstract

Licochalcones extracted from *Glycyrrhiza inflata* are known to have a variety of biological properties such as anti-inflammatory, anti-bacterial, and anti-tumor activities, but their action on platelet aggregation has not yet been reported. Therefore, in this study we investigated the effects of licochalcones on platelet aggregation. Collagen and U46619, a thromboxane A₂ receptor agonist, caused rabbit platelet aggregation, which was reversed by pretreatment with licochalcones A, C and D in concentration-dependent manners. Among these compounds, licochalcone A caused the most potent inhibitory effect on collagen-induced platelet aggregation. However, the licochalcones showed marginal inhibitory effects on thrombin or ADP-induced platelet aggregation. In addition to rabbit platelets, licochalcone A attenuated collagen-induced aggregation in human platelets. Because licochalcone A also inhibited arachidonic acid-induced platelet aggregation and production of thromboxane A₂ induced by collagen in intact platelets, we further examined the direct interaction of licochalcone A with cyclooxygenase (COX)-1. As expected, licochalcone A caused an inhibitory effect on both COX-1 and COX-2 in vitro. Regarding the effect of licochalcone A on COX-1 enzyme reaction kinetics, although licochalcone A showed a stronger inhibition of prostaglandin E₂ synthesis induced by lower concentrations of arachidonic acid, Vmax values in the presence or absence of licochalcone A were comparable, suggesting that it competes with arachidonic acid at the same binding site on COX-1. These results suggest that licochalcones inhibit collagen-induced platelet aggregation accompanied by inhibition of COX-1 activity.

Introduction

Platelets play critical roles in homeostatic functions through their adhesion and aggregation characteristics. When vessel walls are injured, platelets activate immediately to form a plug,
and consequently blood coagulation and thrombi occlude the site of injury. A series of such responses is important for preventing vital blood loss, but it is possible that excessive enhancement of platelet function can lead to ischemia and destruction in vital organs.

Collagen is the most thrombogenic component of the subendothelium. Collagen binds to two receptors on platelets: integrin $\alpha_2\beta_1$, promotes adhesion of platelets to collagen and permits them to interact with glycoprotein VI (GP VI) [1–3]. Then, stimulation of GP VI with collagen causes splicing of arachidonic acid at the inner plasma membranes of platelets by activating phospholipase A$_2$ (PLA$_2$) [4]. The released arachidonic acid is metabolized to thromboxane A$_2$ (TXA$_2$) by cyclooxygenase (COX)-1 and thromboxane synthase (TXS), whose chemical half-time is approximately 30 s. TXA$_2$ released from activated platelets binds to TXA$_2$ receptors to cause platelet morphological changes and aggregation as a positive feedback mediator [5, 6].

Representative anti-platelet agents presently used in the clinic are aspirin and ozagrel, which inhibit TXA$_2$ generation [6], and sarpogrelate and clopidogrel, which are receptor antagonists of 5-hydroxy tryptophan and ADP, respectively [7, 8].

Licochalcones are purified from the licorice species *Glycyrrhiza inflata*, a well-known herb, and are usually contained in Chinese medicines. They have been shown to have a variety of biological properties, such as anti-inflammatory, anti-bacterial, anti-tumor, anti-diabetic activities [9–13]. In addition, it has been reported that glycyrhrizin, which is also a major component of *Glycyrrhiza inflata*, binds to thrombin and inhibits platelet aggregation induced by thrombin with an IC$_{50}$ of approximately 150 $\mu$M [14]. In the present study, we examined the effects of licochalcones on rabbit platelets and human platelets, and demonstrated that licochalcones inhibited platelet aggregation induced by collagen at lower concentrations compared with that by U46619, and was accompanied by an interaction with COX-1.

**Materials and methods**

**Materials**

Licochalcones were provided by Research Laboratory of Minophagen Pharmaceutical Co. Ltd. (Zama, Japan). Prostaglandin (PG) E$_2$, d$_4$-PGE$_2$, U46619, COX-1, COX-2 and TXB$_2$ EIA Kit were purchased from Cayman Chemical Company (Ann Arbor, MI). Collagen (Collagenregent Horm) was purchased from Nycomed Pharma GMBH (Marburg, Germany). Thrombin was purchased from Wako Pure Chemicals (Osaka, Japan). Arachidonic acid and ADP were purchased from Sigma-Aldrich (St. Louis, MO) or Cayman Chemical Company. All other chemicals used were of reagent grade or the highest quality available.

**Preparation of washed platelets**

Washed platelets were prepared from healthy male rabbits (Japanese white rabbits weighing approximately 2.5–3.5 kg), and were collected in plastic tubes containing acid citrate dextrose solution (1/6 volume of blood) composed of citric acid (65 mM), trisodium citrate (85 mM), and D-glucose (2%). Then, the blood was centrifuged at 250 x g for 12 min to obtain platelet-rich plasma. The platelet-rich plasma was centrifuged at 90 x g to remove contaminated erythrocytes and leukocytes, and then centrifuged at 450 x g for 15 min at room temperature (20–25 °C). The pellet was washed twice with Tyrode/HEPES solution (NaCl 138.3 mM, KCl 2.68 mM, MgCl$_2$·6H$_2$O 1.0 mM, NaHCO$_3$ 4.0 mM, HEPES 10 mM, glucose 0.1%, and bovine serum albumin 0.35% at pH 6.35). The resultant pellet was suspended in the second Tyrode/HEPES solution (pH 7.35) with a final density of 3–5 x 10$^6$ platelets/ml [15]. Human washed platelets collected from volunteers were prepared similarly. The present study using human platelets was performed in accordance with a protocol approved by the Ethics Committee of Graduate School of Pharmaceutical Sciences, Tohoku University (approval No.12-04).
Informed consent was obtained in written forms with volunteers’ signatures. The present study using rabbit platelets was performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of the Tohoku University Environmental and Safety Committee (approval No. 22Yaku-Do-29).

**Determination of platelet aggregation**

Platelet aggregation was determined by a standard turbidimetric method using an aggregometer (PAM-6C, Merbanix, Tokyo, Japan), as described previously [15, 16]. Platelet aggregation was expressed as an increase in light transmission. The levels of light transmission were calibrated as 0% for a platelet suspension and 100% for the Tyrode/HEPES solution (pH 7.35). Platelet suspension (3×10⁶ platelets/ml in 0.3 ml) in a cuvette was preincubated at 37°C for 2–3 min under continuous stirring at 1000 rpm. CaCl₂ was then added at a final concentration of 1 mM for 3 min. After the pre-incubation of licochalcones for 5 min, platelet aggregation was initiated by the addition of U46619, collagen, thrombin, ADP or arachidonic acid and monitored for 10 min. Maximal platelet aggregation was achieved at the applied concentration of these stimulators.

**Observation of platelets by scanning electron microscopy**

Samples for observation by scanning electron microscopy were prepared as described previously [16]. Briefly, washed platelet aggregation was initiated by collagen stimulation for 3 min in the presence or absence of licochalcones, and then fixed overnight with 1% glutaraldehyde. Samples were washed twice with phosphate-buffered saline (PBS) for 5 min. The fixed platelets were dehydrated with increasing concentrations of ethanol (50, 70, 80, 90, and 100%) and t-butyl alcohol. The samples were then freeze-dried (ES-2030, Hitachi, Tokyo, Japan) and sputter-coated with Au/Pd with an ion sputter (E-1010, Hitachi, Tokyo, Japan). These samples were observed with a scanning electron microscope (S-3200, Hitachi, Tokyo, Japan).

**Measurement of TXB₂**

Quantification of TXB₂ derived from platelets was performed using a TXB₂ EIA kit. Washed platelets were preincubated at 37°C for 3 min under continuous stirring at 1000 rpm. CaCl₂ (1 mM) was then added for 3 min. After the pre-incubation with licochalcone A for 5 min, platelet aggregation was initiated by addition of collagen (3 μg/ml) and the reactions were stopped by indomethacin/EDTA (25 μM/25 mM) at 4°C. Samples were centrifuged at 2500 × g for 3 min, and then the supernatant was measured by EIA. EIA procedures were performed as indicated in the assay kit instructions.

**Determination of COX-1 and COX-2 activity by LC-MS/MS**

COX inhibition assays were carried out following with modifications of previous report [17]. A 100 mM Tris-HCl buffer (pH 8.0, 222 μL) containing 2 μM hematin and 5 mM L-tryptophan was added to a 2 mL tube. Then, two units of COX-1 or COX-2 (2.5 μL) in Tris-HCl buffer (pH 8.0) and each concentration of the licochalcone A (0–100 μM, 1.25 μL) in DMSO were added to the assay for determining IC₅₀ value, and the sample was incubated at 37°C for 10 min. The reaction was initiated by adding 0.5 μM arachidonic acid (25 μL) in Tris-HCl buffer (pH 8.0). After 2 min, the reaction was terminated by adding 1.0 M HCl (12.5 μL). Then, methanol (5 μL) which included internal standard (IS) (d₄-PGE₂, 50 ng/mL) to calculate the area ratio (peak area of PGE₂/d₄-PGE₂) of compounds for calibration, was added to the sample. After 30 min, PGE₂ and IS were extracted by hexane/ethyl acetate (800 μL, 50/50, v/v...
The sample was mixed and centrifuged at 11,042 × g for 5 min at 4°C, and the organic supernatant was transferred to another tube. Then, the sample was dried under vacuum. Finally, the sample was dissolved in acetonitrile/water (50 μL, 50/50, v/v%) containing 0.1% formic acid, and filtered (0.2 μm pore size, acetyl cellulose, YMC). Five microliters of sample was subjected to LC-MS/MS.

Enzyme kinetics analysis of COX-1

A 100 mM Tris-HCl buffer (pH 8.0, 222 μL) containing 2 μM hematin and 5 mM L-tryptophan was added to a 2 mL tube. Then, two units of COX-1 (2.5 μL) in Tris-HCl buffer (pH 8.0) and 2.5 μM licochalcone A (1.25 μL) in DMSO were added, and the sample was incubated at 37°C for 10 min. The reaction was initiated by adding each concentration of arachidonic acid (0.1–10 μM in 25 μL) in Tris-HCl buffer (pH 8.0). After 2 min, the reaction was terminated by adding 12.5 μL of 1.0 M HCl, and the samples for LC-MS/MS were prepared as described in above section.

LC-MS/MS analysis

The HPLC separations were performed on a Nanospace SI-2 HPLC system (Shiseido, Tokyo) using an XBridge (Waters Corp., Milford, MA) C18 analytical column (50 mm × 2.1 mm i.d., 3.5 μm particle size) with an isocratic elution with a mobile phase consisting of acetonitrile/water (32/68, v/v%) containing 0.1% formic acid. The column oven was maintained at 40°C, and the flow rate was 200 μL/min. The HPLC system was coupled with a Fourier transform mass spectrometer (FTMS, QExactive, Thermo Fisher Scientific, San Jose, CA) equipped with a heated ESI (HESI) source. The ion source parameters were as follows: spray voltage, 3,000 V (negative ion mode); capillary and heater temperature, 250°C and 250°C; sheath gas pressure (nitrogen), 40 psi; auxiliary gas pressure (nitrogen), 5 psi; S-lens RF level, 50%. Samples were analyzed in the targeted-MS² (t-MS²) mode. The t-MS² settings were as follows: resolution, 17,500; auto gain control target, 2E5; isolation width, 2.0 m/z; collision energy, 25% for PGE₂ and d₄-PGE₂. The inclusion list was m/z = 351.21725 for PGE₂, and 355.24226 for d₄-PGE₂. The product ion was m/z = 271.20691 for PGE₂, and 275.23206 for d₄-PGE₂.

Data analysis

Data are expressed as mean±S.E.M. Significant differences were analyzed using Student’s t-test or Tukey–Kramer’s and Dunnett’s methods for multiple comparison.

Results

Licochalcones inhibit platelet aggregation

We first examined the effects of licochalcones on platelet aggregation. There are several molecular species of licochalcones (Fig 1); we used licochalcone A, licochalcone C, and licochalcone D at a concentration of 100 μM. All licochalcones significantly inhibited U46619 (3 μM)- and collagen (3 μg/ml)-induced platelet aggregation in concentration-dependent manners, and collagen-induced platelet aggregation was particularly impaired compared with that induced by U46619 (Fig 2). However, the inhibition of thrombin (0.03 U/ml) or ADP (10 μM)-induced aggregation by licochalcones (100 μM) was marginal (Fig 2A and S1 Fig). Additionally, licochalcone A was more effective in inhibiting platelet aggregation than the other licochalcones. Licochalcone A inhibited the collagen-induced platelet aggregation with an IC₅₀ value of approximately 6.33 μM, whereas licochalcone C was 17.6 μM and licochalcone D was 7.58 μM (Fig 2). We observed the morphology of platelets that aggregated by collagen in the presence
of licochalcones with scanning electron microscopy. Platelets underwent morphological changes when they were stimulated by collagen; however, the platelets did not show any change following pretreatment with licochalcones (Fig 3). We further examined the inhibitory
effect of licochalcone A on human platelet aggregation; licochalcone A also inhibited collagen-induced human platelet aggregation in a concentration-dependent manner (Fig 4).

**Licochalcone A attenuates collagen-induced platelet aggregation accompanied by inhibition of COX-1 activity**

It is well known that collagen causes platelet aggregation mediated through arachidonic acid release by PLA$_2$ at the inner plasma membrane of platelets, and COX inhibitors such as aspirin can block the platelet aggregation induced by collagen [16]. Therefore, we examined whether licochalcone A, which inhibited collagen-induced platelet aggregation at a lower concentration compared with the other licochalcones, also inhibits extrinsic arachidonic acid-induced platelet aggregation. Extrinsic arachidonic acid behaves like internal arachidonic acid because of its lipophilicity. Licochalcone A (>20 μM) completely inhibited platelet aggregation induced by arachidonic acid (30 μM) (Fig 5A). These results suggest that licochalcone A affects molecules downstream of arachidonic acid, possibly COX-1 or TXS, for example.

Arachidonic acid released from the inner membrane interacts with COX-1 and is converted to PGH$_2$, then is sequentially metabolized to prostaglandins including TXA$_2$ and PGE$_2$. Therefore, we examined the amount of TXB$_2$, a metabolite of TXA$_2$, released from platelets by collagen.
Licochalcones inhibit COX activity and platelet aggregation

Fig 4. Concentration-dependent inhibition of collagen-induced human platelet aggregation by licochalcone A. Licochalcone A (10–100 μM) or DMSO (control) were preincubated for 5 min before addition of collagen (5 μg/ml) in the presence of 1 mM CaCl₂. Results are shown as mean±S.E.M. (*P<0.05 compared with control, n = 3, Dunnett’s method).

doi:10.1371/journal.pone.0173628.g004

Fig 5. Concentration-dependent inhibition of arachidonic acid metabolism by licochalcone A. (A) Licochalcone A (2–50 μM) or DMSO (–) was preincubated for 5 min before addition of arachidonic acid (30 μM) in the presence of 1 mM CaCl₂. Results are shown as mean±S.E.M. (*P<0.05 compared with control, n = 3, Dunnett’s method). (B) Licochalcone A (5–50 μM) or DMSO (–) was preincubated for 5 min before addition of collagen (3 μg/ml) in the presence of 1 mM CaCl₂, and terminated by EDTA/indomethacin after incubating for 5 min. Samples were diluted 1/1000 and TXB₂ amount was measured by EIA. Results are shown as mean±S.E.M. (*P<0.05 compared with control, n = 3, Dunnett’s method).

doi:10.1371/journal.pone.0173628.g005
As observed in Fig 5B, licochalcone A reduced the production of TXB$_2$ in a concentration-dependent manner with an IC$_{50}$ value of approximately 2.04 µM, suggesting licochalcone A inhibits COX-1 activity. Hence, we determined whether licochalcone A directly inhibited COX-1 and COX-2 in vitro. After COX-1 or COX-2 was preincubated in the presence of licochalcone A (0.5–100 µM), the enzyme reaction was initiated by the addition of arachidonic acid (0.5 µM), and then the amount of PGE$_2$ was measured by LC-MS/MS, as described in the Materials and Methods (Fig 6A). Licochalcone A reduced PGE$_2$ production in a concentration-dependent manner with IC$_{50}$ values of 0.94 and 1.93 µM for COX-1 and COX-2, respectively, indicating licochalcone A directly inhibited COX-1 and COX-2.

Finally, to assess the inhibitory effect of licochalcone A on COX-1 activity, we also investigated the enzyme reaction kinetics. COX-1 (2 units) was preincubated in the presence or absence of licochalcone A (2.5 µM), then the reaction was started by the addition of arachidonic acid (0.1–10 µM). Newly synthesized PGE$_2$ was measured by LC-MS/MS, as shown in Fig 6A (Fig 6B). In the case of the control (without licochalcone A), the values followed the Michaelis–Menten equation (Km 0.6236 µM, Vmax 3.213 pmol/min). However, in the presence of licochalcone A, PGE$_2$ production resulting from lower concentrations of arachidonic acid was largely suppressed and showed a sigmoid curve. Hence, kinetics parameters were obtained by fitting the values to the sigmoid curve rather than the Michaelis–Menten equation. In this case, Vmax values for vehicle (-) and licochalcone A were 2.791 pmol/min and 2.109 pmol/min, respectively, and Kprime values (concentration corresponding to 1/2

Fig 6. Competitive inhibition of COX-1 and COX-2 activity by licochalcone A in vitro. (A) Hematin (2 µM) and L-tryptophan (5 mM) were added to 100 mM Tris-HCl buffer (pH 8.0), then two units of COX-1 or COX-2 and each concentration of licochalcone A (0.5–100 µM) were added and incubated at 37˚C for 10 min. The reaction was initiated by adding arachidonic acid (0.5 µM). After 2 min, the reaction was terminated by adding 1.0 M HCl, and then the amount of PGE$_2$ was measured by LC-MS/MS. Results are shown as mean±S.E.M. (*P<0.05 compared with control, n = 3, Dunnett’s method). (B) Two units of COX-1 and licochalcone A (2.5 µM) were incubated at 37˚C for 10 min as described above. The reaction was initiated by adding each concentration of arachidonic acid (0.1–10 µM). After 2 min, the reaction was terminated by adding 1.0 M HCl, and then the amount of PGE$_2$ was measured by LC-MS/MS. Results are shown as mean±S.E.M. (*P<0.05 compared with control, n = 3, Student’s t-test).

doi:10.1371/journal.pone.0173628.g006
Vmax) were 0.1097 μM and 2.017 μM. Vmax values were not significant and comparable regardless of licochalcone A, and Kprime values were significantly distinct following the addition of licochalcone A, suggesting that licochalcone A competitively inhibits COX-1 activity with arachidonic acid.

**Discussion**

In the present study, we investigated the effects of licochalcones, which are contained in licorice and are frequently used in Chinese medicine, on human and rabbit platelet aggregation. The species of licorice used in the present study are more abundant in licochalcones than other species. First, we examined the effects of licochalcones on rabbit washed platelet aggregation. All licochalcones largely inhibited platelet aggregation induced by both U46619 and collagen, but their inhibitory effects on collagen-induced platelet aggregation were 10-fold more effective than that induced by U46619 with regards to IC50 (Fig 2). Therefore, we supposed that licochalcones acted more specifically on the aggregation induced by collagen, and licochalcone A was the most effective. Importantly, licochalcone A suppressed human platelet aggregation in addition to rabbit platelets (Fig 4). Furthermore, licochalcone A suppressed arachidonic acid-induced aggregation in a concentration-dependent manner, as in the case of collagen-induced aggregation (Fig 5A); therefore, we postulated that licochalcone A acted on COX-1 or TXS, but not on release of arachidonic acid from plasma membranes. Actually, we observed that licochalcone A had a direct inhibitory action on COX-1 in vitro (Fig 6) and inhibited production of TXA2, in intact platelets in a similar concentration range (Fig 5B). In addition, this range of concentration-dependency (IC50 2.04 μM) is almost comparable with that of platelet aggregation induced by collagen (3 μg/ml) IC50 6.33 μM (Fig 2B). Although there is a slight difference about these IC50 values, we consider this results from the different methodology of these assays, i.e. we measured the accumulation of TXB2 for 5 min, whereas the platelet aggregation reflected the unstable TXA2 levels induced by collagen present at each time points.

These results strongly suggest that licochalcone A inhibits platelet aggregation by suppressing COX-1 activity. However, licochalcone A also inhibited the platelet aggregation induced by U46619 at higher concentrations (Fig 2). COX inhibitors generally do not suppress platelet aggregation induced by U46619 [18, 19], so this result suggests the possibility that licochalcones also act on molecules other than COX-1, with lower affinity in platelets. For example, licochalcones at higher concentration may act on TP directly as TP antagonists. As it has been reported that licochalcone A interacts with inhibitor-κB kinase (IKK) [20], it is necessary to identify the other molecules interacting with licochalcone A.

It has been demonstrated that the thrombin-induced platelet aggregation does not require TXA2 production through COX. Thus, COX inhibitors do not show inhibitory effects on the aggregation by thrombin in case of U46619 [21, 22]. In case of thrombin, intracellular Ca2+ increase via protease-activated receptors (thrombin receptors)/Gq/PLC-β pathway is essential. Hence, we assume that licochalcones did not inhibit the thrombin-induced aggregation efficiently (Fig 2). In addition, licochalcone A did not block the ADP-induced platelet aggregation (S1 Fig) as it has been shown that the ADP-induced platelet aggregation does not require COX activity [23, 24]. On the other hand, platelet aggregation by collagen requires COX activity, we and another group showed that NSAIDs such as aspirin and indomethacin completely blocked the platelet aggregation by collagen [16, 22]. In this study, we clarified that licochalcones were COX inhibitors, this is the reason to explain the different results between collagen and thrombin or ADP.

It has been shown that COX-1 isoforms predominantly localize at intracellular membranes including the endoplasmic reticulum, nuclear envelope, and Golgi apparatus [25, 26]; that is,
COX-1 isoform subcellular localization is not mainly cytosolic, and COX-1 is embedded in these membranes. Licochalcone A could inhibit collagen-aggregation after a brief period of incubation such as 15 s. Even though precise COX-1 localization in platelets has not been clarified, we can suppose from this result that licochalcones are not completely incorporated into platelets, but approach COX-1 that is located in neighboring platelet plasma membranes and does not allow arachidonic acid to reach the active site of COX-1. Otherwise, the composition of the lipid bilayers of platelet plasma membranes may differ from that of other cells, and licochalcones are easily incorporated into intracellular regions.

Using LC-MS/MS system for PG quantitation, we determined the IC$_{50}$ values of licochalcone A in vitro for COX-1 and COX-2 to be 0.94 μM and 1.93 μM, respectively (Fig 6A), and the ratio of IC$_{50}$ of COX-1/COX-2 as being 0.49. Hence, licochalcone A is not a selective inhibitor for these COX isoforms compared with a COX-2-selective inhibitor such as celecoxib, the ratio of which is approximately 9.49 for ovine COX-1/ovine COX-2 and 600 for ovine COX-1/human COX-2 [17]. However, Song et al. showed that licochalcone A did not cause inhibition of COX-2 activity in human keratinocytes [27], whereas we demonstrated that licochalcone A clearly blocked both COX isoforms in a concentration-dependent manner. The discrepancy between these results cannot be explained so far.

In addition, we determined the reaction rate of COX-1 and analyzed the inhibitory mechanism of licochalcone A by enzyme kinetics. The previously reported Km value of COX-1 was in the range of 0.75–4.67 μM [17, 28, 29], which is comparable with our value of 0.6236 μM (Fig 6B). In addition, the Vmax values were comparable regardless of licochalcone A, suggesting licochalcone A causes competitive inhibition of the COX-1 reaction with arachidonic acid. However, in the presence of licochalcone A, COX-1 activity was strongly attenuated when the concentration of arachidonic acid was low (Fig 6B), which was not applied to the Michaelis–Menten equation but rather fitted to a sigmoid curve. It is not easy to interpret this result, but we assume that COX-1 conformation was changed and it lost affinity to arachidonic acid by binding to licochalcone A. However, higher concentrations of arachidonic acid could compete with licochalcone A and recover the affinity to COX-1, resulting in a concentration-dependent sigmoid curve with equivalent Vmax values.

Licochalcones contain an α,β-unsaturated ketone structure, and nucleophiles such as the thiol group of cysteine can bind to licochalcones easily in physiological conditions by the Michael addition reaction. In fact, we could observe covalent binding between licochalcone A and cysteine, and it has been shown that Cys179 in IKKβ is an important amino acid residue for inhibition of IKKβ-mediated nuclear factor-κB activation by licochalcone A [20]. Furthermore, a reduced licochalcone A that lacks a double bond failed to inhibit IKK-mediated nuclear factor-κB activation [30]. These reports suggest the possibility that licochalcone A binds to the cysteine residues of various proteins by the Michael addition reaction. Because COX-1 has a free cysteine residue (Cys512) near the active site [31], we speculated that licochalcones bound to COX-1 at this Cys512, and thus attempted detection of licochalcone-bound COX-1 by mass spectrometry. However, we failed to prove our hypothesis. The interaction between licochalcones and COX-1 may be unstable and reversible as high concentrations of arachidonic acid can replace it (Fig 6B). Further study is necessary to identify the binding site of licochalcones on COX-1 and COX-2.

Conclusions

In conclusion, we found that licochalcone A isolated from licorice species *Glycyrrhiza inflata* suppressed collagen-induced platelet aggregation by inhibiting COX-1 isoforms. Further study is necessary to clarify the detailed mechanism of COX inhibition by licochalcone A and
another potential mechanism of inhibition by other platelet activators including thromboxane A₂.

Supporting information
S1 Fig. Effect of licochalcone A on ADP-induced platelet aggregation. Licochalcone A (Lico. A, 10 or 100 μM) or DMSO (-) was preincubated for 5 min before addition of ADP (10 μM) in the presence of 1 mM CaCl₂. Results are shown as mean±S.E.M. (P<0.05 compared with control, n = 4–7, Dunnett’s method).

Acknowledgments
We thank Dr. Kazuki Abe and Dr. Hideo Inoue (Research Laboratory of Minophagen Pharmaceutical Co. Ltd., Zama, Japan) for providing licochalcones. We thank Dr. Yosuke Okamoto (Yamagata University, Japan) for the statistical analysis. We thank Dr. Teigo Asai (Tokyo University, Japan) for critical scientific discussions.

Author Contributions
Conceptualization: NN.
Formal analysis: AOT D. Sugawara YO D. Saigusa.
Funding acquisition: NN.
Investigation: AOT D. Sugawara TT YO TM CT D. Saigusa.
Project administration: YO NN.
Supervision: MI YO TM D. Saigusa YT KI NN.
Validation: TM.
Writing – original draft: AOT D. Sugawara.
Writing – review & editing: MI YO TM D. Saigusa YT KI.

References
1. Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res. 2004; 114(4):221–233. doi: 10.1016/j.thromres.2004.06.046 PMID: 15381385
2. Nieswandt B, Varga-Szabo D, Elvers M. Integrins in platelet activation. J Thromb Haemost. 2009; 7 Suppl 1:206–209.
3. Rivera J, Lozano ML, Navarro-Nunez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 2009; 94(5):700–711. doi: 10.3324/haematol.2008.003178 PMID: 19286685
4. Surin WR, Barthwal MK, Dikshit M. Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. Thromb Res. 2008; 122(6):786–803. doi: 10.1016/j.thromres.2007.10.005 PMID: 18045662
5. De La Cruz JP, Villalobos MA, Escalante R, Guerrero A, Arrebola MM, Sanchez de La Cuesta F. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction. Br J Pharmacol. 2002; 137(7):1082–1088. doi: 10.1038/sj.bjp.0704963 PMID: 12429851
6. Nakahata N. Thromboxane A₂: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008; 118(1):18–35. doi: 10.1016/j.pharmthera.2008.01.001 PMID: 18374420
7. Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther. 2004; 104(1):59–81. doi: 10.1016/j.pharmthera.2004.08.005 PMID: 15500909
8. Choi J, Kermode JC. New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects. Mol Interact. 2011; 11(2):111–123. doi: 10.1016/j.molint.2011.02.001 PMID: 2150471

9. Park HG, Bak EJ, Woo GH, Kim JM, Quan Z, Kim JM, et al. Licochalcone E has an antidiabetic effect. J Nutr Biochem. 2012; 23(7):759–767. doi: 10.1016/j.jnutbio.2011.03.021 PMID: 21840191

10. Kim YH, Shin EK, Kim DH, Lee HH, Park JH, Kim JK. Antiangiogenic effect of licochalcone A. Biochem Pharmacol. 2010; 80(8):1152–1159. doi: 10.1016/j.bcp.2010.07.006 PMID: 20637733

11. Kim JK, Shin EK, Park JH, Kim YH, Park JH. Antitumor and antimetastatic effects of licochalcone A in mouse models. J Mol Med (Berl). 2010; 88(8):829–838.

12. Fnis-Møller A, Chen M, Fuursted K, Christensen SB, Kharazmi A. In vitro antimycobacterial and antileishmanial activity of licochalcone A isolated from Glycyrrhiza inflata. Z Naturforsch C. 2008; 63(5–6):361–365. PMID: 18669021

13. Cui Y, Ao M, Li W, Hu J, Yu L. Anti-inflammatory activity of licochalcone A from Chinese licorice roots. Pflugers Arch. 2002; 443(2):150–159. doi: 10.1007/s004240010205 PMID: 12711701

14. Francischetti IM, Monteiro RQ, Guimaraes JA. Identification of glycyrrhizin as a thrombin inhibitor. Biochem Biophys Res Commun. 1997; 235(1):259–263. PMID: 9196073

15. Ishawashita M, Oka N, Ohkubo S, Saito M, Nakahata N. Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A(2) receptor antagonist. Jpn J Pharmacol. 2007; 570(1–3):38–42. doi: 10.1016/j.ejphar.2007.05.073 PMID: 17618620

16. Mori K, Kikuchi H, Obara Y, Ishawashita M, Azumi Y, Kinugasa S, et al. Inhibitory effect of hericenone B from Hericium erinaceum on collagen-induced platelet aggregation. Phytomedicine. 2010; 17(14):1082–1085. doi: 10.1016/j.phymed.2010.05.004 PMID: 20637576

17. Cao H, Yu R, Tao Y, Nikolic D, van Breemen RB. Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2011; 54(1):230–235. doi: 10.1016/j.jpba.2010.08.001 PMID: 20817448

18. Armstrong PC, Kirkby NG, Zain ZN, Emerson M, Mitchell JA, Warner TD. Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One. 2011; 6(5):e20062. doi: 10.1371/journal.pone.0020062 PMID: 21629780

19. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Santana Sorensen A. The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. J Thromb Haemost. 2011; 9(10):2109–2111. doi: 10.1111/j.1538-7836.2011.04446.x PMID: 21777369

20. Funakoshi-Tago M, Tanabe S, Tago K, Itoh H, Mashino T, Sonoda Y, et al. Licochalcone A potently inhibits tumor necrosis factor alpha-induced nuclear factor-kappaB activation through the direct inhibition of IkappaB kinase complex activation. Mol Pharmacol. 2009; 76(4):745–753. doi: 10.1124/mol.109.057448 PMID: 19592502

21. McNicol A, Robson CA. Thrombin receptor-activating peptide releases arachidonic acid from human platelets: A comparison with thrombin and trypsin. J Pharmacol Exp Ther. 1997; 281(2):861–867. PMID: 9152395

22. Yacoub D, Theoret JF, Villeneuve L, Abou-Saleh H, Mourad W, Allen BG, et al. Essential role of protein kinase C delta in platelet signaling, alpha IIb beta 3 activation, and thromboxane A2 release. J Biol Chem. 2006; 281(40):30024–30035. doi: 10.1074/jbc.M604504200 PMID: 16895913

23. Ting HJ, Murray WJ, Khasawneh FT. Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane A(2) receptor. Acta Pharmacol Sin. 2010; 31(2):150–159. doi: 10.1038/aps.2009.195 PMID: 20139897

24. Naito J, Komatsu H, Ujiiie A, Hamano S, Kubota T, Tsuboshima M. Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur J Pharmacol. 1983; 91(1):41–48. PMID: 6413227

25. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 1995; 270(18):10902–10908. PMID: 7738031

26. Grewal S, Ponnambalam S, Walker JH. Association of cPLA2-alpha and COX-1 with the Golgi apparatus of A549 human lung epithelial cells. J Cell Sci. 2003; 116(PT 11):2303–2310. doi: 10.1242/jcs.00446 PMID: 12711701

27. Song NR, Kim JE, Park JS, Kim JR, Kang H, Lee E, et al. Licochalcone A, a polyphenol present in licorice, suppresses UV-induced COX-2 expression by targeting PI3K, MEK1, and B-Raf. Int J Mol Sci. 2015; 16(3):4453–4470. doi: 10.3390/ijms16034453 PMID: 25710724

28. Nakatani K, Nakahata N, Arakawa T, Yasuda H, Ohizumi Y. Inhibition of cyclooxygenase and prostaglandin E2 synthesis by gamma-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. Biochem Pharmacol. 2002; 63(1):73–79. PMID: 11754876
29. Xu Y, Phipps S, Turner MJ, Simmons DL. The N-terminus of COX-1 and its effect on cyclooxygenase-1 catalytic activity. J Genet Genomics. 2010; 37(2):117–123. doi: 10.1016/S1673-8527(09)60030-8 PMID: 20227045

30. Funakoshi-Tago M, Nakamura K, Tsuruya R, Hatanaka M, Mashino T, Sonoda Y, et al. The fixed structure of Licochalcone A by alpha, beta-unsaturated ketone is necessary for anti-inflammatory activity through the inhibition of NF-kappaB activation. Int Immunopharmacol. 2010; 10(5):562–571. doi: 10.1016/j.intimp.2010.02.003 PMID: 20153843

31. Thuresson ED, Lakkides KM, Rieke CJ, Sun Y, Wingerd BA, Micielli R, et al. Prostaglandin endoperoxide H synthase-1: the functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J Biol Chem. 2001; 276(13):10347–10357. doi: 10.1074/jbc.M009377200 PMID: 11121412